Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Chemical Biology and Drug Design is Scopus-indexed (Q2, CiteScore 6.1), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by John Wiley and Sons Inc.
Checked against the index lists dated .
ISSN 1747-0277Verify ISSN ↗1747-0285Verify ISSN ↗
Publisher: John Wiley and Sons Inc
Cost to publish: About US$3,920 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Organic Chemistry | 60 / 215 | 72nd | Q2 |
| Pharmacology | 102 / 328 | 69th | Q2 |
| Drug Discovery | 58 / 161 | 64th | Q2 |
| Biochemistry | 171 / 448 | 61st | Q2 |
| Molecular Medicine | 80 / 179 | 55th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2006–present, best quartile Q2, CiteScore 6.1.
Chemical Biology and Drug Design is Q2 in Organic Chemistry (rank 60 of 215), Q2 in Pharmacology (rank 102 of 328) and Q2 in Drug Discovery (rank 58 of 161), by CiteScore 2025. It is ranked in 5 subject areas in all.
Chemical Biology and Drug Design is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 6.1, which places it in quartile Q2 at the 72nd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.666, quartile Q2, with an H-index of 102.
The publisher lists an article processing charge of about US$3,920 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Chemical Biology and Drug Design is published by John Wiley and Sons Inc. Its print ISSN is 1747-0277 and its online ISSN is 1747-0285.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Chemical Biology and Drug Design has an h-index of 99 and a 2-year mean of 3.04 citations per paper (OpenAlex). Its Scopus CiteScore is 6.1, quartile Q2. On 2-year citations it ranks #84 of 210 Scopus journals in Organic Chemistry.
Chemical Biology and Drug Design published 216 papers in 2025; its busiest recent year was 2024 with 254. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2026), authors are most often from China (33.8%), India (15%) and Türkiye (11.8%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 11 retracted papers are recorded (2.6 per 1,000 papers). The Problematic Paper Screener flags 5 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.